Richard W. Paul & Associates, LLC Arbutus Biopharma Corp Put Options Transaction History
Richard W. Paul & Associates, LLC
- $259 Billion
- Q2 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding ABUS
# of Institutions
137Shares Held
95.4MCall Options Held
3.44MPut Options Held
377K-
Morgan Stanley New York, NY21MShares$94.5 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$58 Million30.08% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$52.1 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.57MShares$38.7 Million10.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.02MShares$31.7 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $676M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...